Table 1.

Overview of different combinations of chemotherapy and ICI used in nine research articles comparing multiple therapeutic regimens.

Author – Year	Cancer type	ICI	Chemo-therapy	Regimen of administration tested	Superior regimen	Limitations
Lesterhuis WJ. et al. – 2013 (54)	Meso-thelioma	anti-CTLA4	Gemcitabine	• Simultaneous • Sequential – first chemo • Sequential – first ICI	Simultaneous	s.c. mouse model
Martin-Ruiz A. et al. – 2020 (55)	Lung carcinoma	anti-PD-1	Cisplatin	• Simultaneous • Sequential – first chemo • Sequential – first ICI	Simultaneous	Immuno-deficient mouse model (NSG)
Zhao X. et al. – 2020 (56)	Colorectal carcinoma	anti-PD-1	5-fluorouracil	• Simultaneous • Sequential – first chemo	Sequential – first chemo	s.c. mouse model
Fu D. et al. – 2020 (57)	Colorectal carcinoma	anti-PD-1/L1	Cisplatin or Oxaliplatin	• Simultaneous • Sequential – first chemo, 3 days later ICI • Sequential first – chemo, 6 days later ICI	Sequential – first chemo, 3 days later ICI	s.c. mouse model
Golchin S. et al. – 2019 (58)	Colorectal carcinoma	anti-PD-L1	Oxaliplatin	• Simultaneous • Sequential – first chemo • Sequential – first ICI	Sequential – first ICI	s.c. mouse model
Alimohammadi R. et al. – 2020 (59)	Melanoma	anti-CTLA-4	Doxel	• Simultaneous • Sequential – first chemo • Sequential – first ICI	Sequential – first ICI	/
Yan Y. et al. – 2018 (60)	Melanoma	anti-PD-1/L1	Carboplatin + Paclitaxel	• Simultaneous • First ICI followed by simultaneous ICI + chemo	First ICI followed by simultaneous ICI + chemo	/
Coosemans et al. – 2019 (53)	Ovarian cancer	anti-PD-1	Carboplatin + Paclitaxel	• Simultaneous – first ICI followed by ICI + chemo • Simultaneous – first chemo followed by chemo + ICI	Simultaneous – first ICI followed by ICI + chemo	/
Riva et al. – 2020 (61)	High-Grade Glioma	anti-PD-1	Temozolomide	• Simultaneous • Sequential – first chemo • Sequential – first ICI	No difference	/

(ICI, immune checkpoint inhibitor; s.c., subcutaneous; NSG, NOD scid gamma).